Revista de gastroenterologia de Mexico (English)最新文献_第4页

Fecal microbiota transplantation through colonoscopy in the treatment of recurrent Clostridioides difficile: Experience at a university center 通过结肠镜进行粪便微生物群移植治疗复发性艰难梭菌：一家大学中心的经验。

Revista de gastroenterologia de Mexico (English) Pub Date : 2024-10-01 DOI: 10.1016/j.rgmxen.2024.03.004

R. Quera , P. Nuñez , C. von Muhlenbrock , R. Espinoza

{"title":"Fecal microbiota transplantation through colonoscopy in the treatment of recurrent Clostridioides difficile: Experience at a university center","authors":"R. Quera , P. Nuñez , C. von Muhlenbrock , R. Espinoza","doi":"10.1016/j.rgmxen.2024.03.004","DOIUrl":"10.1016/j.rgmxen.2024.03.004","url":null,"abstract":"<div><h3>Introduction</h3><div>The majority of cases of <em>Clostridioides difficile</em> infection (CDI) respond to antibiotic treatment. Fecal microbiota transplantation (FMT) has been accepted as an effective treatment in cases of recurrent CDI.</div></div><div><h3>Aim</h3><div>Our aim was to describe the clinical results of FMT performed for the treatment of recurrent CDI.</div></div><div><h3>Material and methods</h3><div>The study was conducted on patients with recurrent CDI treated with FMT through colonoscopy, within the time frame of January 2021 and December 2023. Demographic and clinical data were collected, including pre-FMT treatment data, the FMT success rate, and clinical progression during follow-up. Telephone surveys were carried out to evaluate satisfaction.</div></div><div><h3>Results</h3><div>Thirteen patients with a mean age of 55 years underwent FMT (including 7 patients above 65 years of age and one pregnant woman). Patients presented with a median of 3 previous episodes of CDI (range 2-4). The median time interval from first episode of CDI to FMT was 4 months (range 3-10). The effectiveness of a single FMT session was 100%. During post-FMT follow-up (median of 11 months, range 3-32), 3 patients have presented with a new CDI episode, and a successful second FMT was performed on 2 of them. No adverse events were registered, and all patients had a positive perception of FMT.</div></div><div><h3>Conclusions</h3><div>In the present study, despite its small size, FMT through colonoscopy was shown to be a safe, effective, and lasting therapy in cases of recurrent CDI, concurring with results from larger studies.</div></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 4","pages":"Pages 513-520"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142407313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to Hernández-Almonacid and Marín-Quintero concerning their comments on the article: “Metabolic disorders across the body mass index spectrum in a Colombian population with nonalcoholic fatty liver disease” 就 Hernández-Almonacid 和 Marín-Quintero 对文章的评论做出答复："哥伦比亚非酒精性脂肪肝患者的体重指数谱代谢紊乱"。

Revista de gastroenterologia de Mexico (English) Pub Date : 2024-10-01 DOI: 10.1016/j.rgmxen.2024.08.002

C.E. Builes-Montaño , E. Pérez-Giraldo , S. Castro-Sánchez , N.A. Rojas-Henao , O.M. Santos-Sánchez , J.C. Restrepo-Gutierrez

引用次数: 0

Gastrointestinal adverse effects of old and new antidiabetics: How do we deal with them in real life? 新旧抗糖尿病药物的胃肠道不良反应：在现实生活中如何应对？

Revista de gastroenterologia de Mexico (English) Pub Date : 2024-10-01 DOI: 10.1016/j.rgmxen.2024.10.008

J.R. Barrientos-Ávalos , E.C. Morel-Cerda , F.A. Félix-Téllez , B.E. Vidrio-Huerta , A.R. Aceves-Ayala , Á.R. Flores-Rendón , J.A. Velarde-Ruiz Velasco

{"title":"Gastrointestinal adverse effects of old and new antidiabetics: How do we deal with them in real life?","authors":"J.R. Barrientos-Ávalos , E.C. Morel-Cerda , F.A. Félix-Téllez , B.E. Vidrio-Huerta , A.R. Aceves-Ayala , Á.R. Flores-Rendón , J.A. Velarde-Ruiz Velasco","doi":"10.1016/j.rgmxen.2024.10.008","DOIUrl":"10.1016/j.rgmxen.2024.10.008","url":null,"abstract":"<div><div>Diabetes is a public health problem with an estimated worldwide prevalence of 10% and a prevalence of 12% in Mexico. The costs resulting from this chronic-degenerative disease are significant. Treatment for diabetes involves different medication groups, some of which can cause significant gastrointestinal adverse effects, such as dyspepsia, nausea, vomiting, bloating, diarrhea, and constipation. The medications most frequently associated with said adverse effects are metformin, acarbose, and GLP-1 agonists. Gastrointestinal adverse effects negatively impact the quality of life and management of patients with diabetes. The factors of visceral neuropathy, acute dysglycemia, dysbiosis, and intestinal bacterial overgrowth contribute to the gastrointestinal symptoms in patients with diabetes, making it necessary to consider multiple etiologic factors in the presence of gastrointestinal symptoms, and not exclusively attribute them to the use of antidiabetics. Personalized treatment, considering gastrointestinal comorbidity and the type of drug utilized, is essential for mitigating the adverse effects and improving the quality of life in patients with diabetes. The aim of the present narrative review was to describe the gastrointestinal adverse effects of the antidiabetic drugs, their pathophysiologic mechanisms, and the corresponding therapeutic measures.</div></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 4","pages":"Pages 521-532"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142514269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative evaluation of APRI, FIB-4, HFS, and NFS: Scoring tools for liver fibrosis in a Mexican population with MASLD APRI、FIB-4、HFS 和 NFS 的比较评估：墨西哥 MASLD 患者的肝纤维化评分工具。

Revista de gastroenterologia de Mexico (English) Pub Date : 2024-10-01 DOI: 10.1016/j.rgmxen.2024.09.002

B.A. Priego-Parra , A. Triana-Romero , R. Bernal-Reyes , M.E. Icaza-Chávez , S.E. Martínez-Vázquez , M. Amieva-Balmori , A.D. Cano-Contreras , H. Vivanco-Cid , J.M. Remes-Troche

{"title":"Comparative evaluation of APRI, FIB-4, HFS, and NFS: Scoring tools for liver fibrosis in a Mexican population with MASLD","authors":"B.A. Priego-Parra , A. Triana-Romero , R. Bernal-Reyes , M.E. Icaza-Chávez , S.E. Martínez-Vázquez , M. Amieva-Balmori , A.D. Cano-Contreras , H. Vivanco-Cid , J.M. Remes-Troche","doi":"10.1016/j.rgmxen.2024.09.002","DOIUrl":"10.1016/j.rgmxen.2024.09.002","url":null,"abstract":"<div><h3>Introduction and aim</h3><div>Liver fibrosis is a complication of metabolic dysfunction-associated steatotic liver disease (MASLD). Given the limitations and risks of liver biopsy, examining noninvasive scoring systems that are affordable for the population is necessary. Our aim was to evaluate and compare the diagnostic yield of the APRI, FIB-4, NAFLD score, and Hepamet fibrosis score instruments for detecting liver fibrosis in Mexican subjects with MASLD.</div></div><div><h3>Material and methods</h3><div>A retrospective study was conducted on a sample of subjects with MASLD. Liver fibrosis was calculated through transient liver elastography. Sociodemographic, epidemiologic, and biochemical variables were evaluated. Scores were calculated utilizing the fibrosis-4 (FIB-4) index, the aspartate aminotransaminase-to-platelet ratio index (APRI), the Hepamet fibrosis score (HFS), and the NAFLD score (NFS), and then compared. ROC curves were constructed, and the optimum cutoff points were determined utilizing the Youden index. Sensitivity, specificity, positive predictive value, negative predictive value, and likelihood ratio were calculated.</div></div><div><h3>Results</h3><div>The study included 194 subjects (63% women), of whom 150 (77.3%) were classified with MASLD and 44 (22.7%) as controls with no liver disease. There was a 15.3% prevalence of advanced fibrosis. The cutoff points of 0.57 for APRI, 1.85 for FIB-4, 0.08 for HFS, and −0.058 for NFS showed diagnostic yields with areas under the ROC curves of 0.79, 0.80, 0.70, and 0.68, respectively.</div></div><div><h3>Conclusion</h3><div>The APRI, FIB-4, NFS, and HFS scores are useful for evaluating liver fibrosis in Mexican subjects with MASLD. Better diagnostic yield was found with the FIB-4 and APRI scores.</div></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 4","pages":"Pages 498-505"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to the editorial commentary by Crisostomo-Estrada JK, et al. on the article “Performance of the predictive criteria of the American Society for Gastrointestinal Endoscopy in the diagnosis of choledocholithiasis at a secondary care public hospital in the state of Nuevo León, Mexico” 对 Crisostomo-Estrada JK 等人就 "美国消化内镜学会预测标准在墨西哥新莱昂州一家二级公立医院诊断胆总管结石中的应用 "一文发表的社论评论的回应。

Revista de gastroenterologia de Mexico (English) Pub Date : 2024-10-01 DOI: 10.1016/j.rgmxen.2024.06.004

C. Ovalle-Chao

引用次数: 0

Lymphangioma of the pancreas diagnosed through endoscopic ultrasound-guided fine-needle aspiration biopsy: A case report 通过内镜超声引导下细针穿刺活检确诊的胰腺淋巴管瘤：病例报告。

Revista de gastroenterologia de Mexico (English) Pub Date : 2024-10-01 DOI: 10.1016/j.rgmxen.2024.05.004

J.M. Jiménez-Gutiérrez , J.O. Alonso-Lárraga , L.F. Villegas-González , A.Y. Ortega-Caballero

引用次数: 0

Cricopharyngeal achalasia: A rare cause of dysphagia in infancy 环咽贲门失弛缓症：婴儿期吞咽困难的罕见病因。

Revista de gastroenterologia de Mexico (English) Pub Date : 2024-10-01 DOI: 10.1016/j.rgmxen.2024.10.006

C.A. Cuadros-Mendoza, K. Lozano-Agudelo, M.C. Gómez-Franco, L.V. Parra Izquierdo

引用次数: 0

Neurofibromatosis type 1-associated gastrointestinal stromal tumor of the stomach 神经纤维瘤病 1 型相关胃肠道间质瘤。

Revista de gastroenterologia de Mexico (English) Pub Date : 2024-10-01 DOI: 10.1016/j.rgmxen.2024.10.003

M. Cernat , L. Antoci , I. Mishin

引用次数: 0

Comments on the article, “Performance of the predictive criteria of the American Society for Gastrointestinal Endoscopy in the diagnosis of choledocholithiasis at a secondary care public hospital in the state of Nuevo León, Mexico” 对文章 "墨西哥新莱昂州一家二级公立医院采用美国消化内镜学会预测标准诊断胆总管结石的效果 "的评论。

Revista de gastroenterologia de Mexico (English) Pub Date : 2024-10-01 DOI: 10.1016/j.rgmxen.2024.06.005

J.K. Crisostomo-Estrada , N.Y. Gonzales-Reyes , Y.I. Ñahui Sullca

引用次数: 0

Experience of endoscopy versus surgery as initial management of chronic pancreatitis 慢性胰腺炎初始治疗中内镜检查与手术的对比经验。

Revista de gastroenterologia de Mexico (English) Pub Date : 2024-10-01 DOI: 10.1016/j.rgmxen.2024.03.003

U. Lara-Orozco , V. Ortiz-Higareda , J.L. Martínez-Ordaz , E.V. Rodríguez-Negrete , Y. Choncoa-Valderrama

{"title":"Experience of endoscopy versus surgery as initial management of chronic pancreatitis","authors":"U. Lara-Orozco , V. Ortiz-Higareda , J.L. Martínez-Ordaz , E.V. Rodríguez-Negrete , Y. Choncoa-Valderrama","doi":"10.1016/j.rgmxen.2024.03.003","DOIUrl":"10.1016/j.rgmxen.2024.03.003","url":null,"abstract":"<div><h3>Introduction and aim</h3><div>Chronic pancreatitis is a pathologic fibroinflammatory syndrome of the pancreas. Treatment includes medical management and endoscopic and/or surgical interventions. Our aim was to describe progression in patients with chronic pancreatitis whose initial management was either endoscopic or surgical.</div></div><div><h3>Material and methods</h3><div>A retrospective, analytic, observational, and longitudinal study was conducted that included patients diagnosed with chronic pancreatitis treated at the <em>Hospital de Especialidades</em> of the <em>Centro Médico Nacional Siglo XXI</em> from 2015 to 2021.</div></div><div><h3>Results</h3><div>Twenty-two patients were included in the study; 12 underwent endoscopy and 10 underwent surgery. The mean number of interventions performed was 3 in the endoscopic management group and 1.1 in the surgical management group (<em>p</em> = 0.001). Regarding pain remission (partial or total), results were statistically significant in favor of surgical management (<em>p</em> = 0.035). Of the 12 patients that initially underwent endoscopy, 7 (58.3%) eventually required surgery during follow-up. There were no statistically significant differences with respect to opioid and pancreatin use, readmissions, weight loss, steatorrhea, newly diagnosed diabetes, or deaths during follow-up.</div></div><div><h3>Conclusion</h3><div>Pain is the main indication for invasive treatment, whether endoscopic or surgical, in patients with chronic pancreatitis. Slightly more than half of the patients that were initially managed endoscopically required surgery during follow-up. Management decisions should be multidisciplinary and individualized for each patient.</div></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 4","pages":"Pages 491-497"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0